EADO 2022 | How to manage chronic non-cutaneous immune-related toxicites

Jeffrey Weber, MD, PhD, NYU Langone Medical Center, New York, NY, discusses immune-related adverse events (AEs) of treating melanoma and how they can be managed. Non-cutaneous adverse events include hepatitis, myocarditis and endocrinopathies. Corticosteroids are the gold standard for treating such immune-related AE’s, however, immune-related AEs can be steroid refractory. With colitis, for example, this can be treated with infliximab or the TNF-blocking antibody, remicade. Dr. Weber emphasizes patients should be treated with steroids for at least 30 days, however, caution should be taken with repeated treatment as this can lead to an increased risk of infection by decreasing the benefit of the immune checkpoint inhibitor. This interview took place at the EADO 2022 congress.